Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
Mohammad Krayem, Ahmad Najem, Fabrice Journe, Renato Morandini, François Sales, Ahmad Awada, Ghanem E. Ghanem
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMelanoma and MAPK Pathways · Computational Drug Discovery Methods · Microbial Metabolism and Applications
This article has been retracted: Multiple internal duplications of western blot images illustrating the data of different experiments have been discovered throughout Figure 3C. In addition, Figure 3C also contains blots images from Figure 2A in an earlier published paper [1]. Therefore, with the agreement of all authors, the Scientific Integrity office at Oncotarget has decided to retract this paper.
Original article: Oncotarget. 2018; 9:31888–31903. 31888-31903. https://doi.org/10.18632/oncotarget.25879
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Krayem M , Journe F , Wiedig M , Morandini R , Najem A , Salès F , van Kempen LC , Sibille C , Awada A , Marine JC , Ghanem G . p 53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V 600E/K)BRAF melanoma to vemurafenib. Eur J Cancer. 2016; 55:98–110. 10.1016/j.ejca.2015.12.002. 26790143 · doi ↗ · pubmed ↗